2-(Boc-氨基)-2-(3-吡啶)乙酸 | 347187-29-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(Boc-氨基)-2-(3-吡啶)乙酸
• 中文别名: 2-(Boc-氨基)-2-(3-吡啶基)乙酸；2-(BOC-氨基)-2-(3-吡啶基)乙酸
• 英文名称: 2-((tert-butoxycarbonyl)amino)-2-(pyridin-3-yl)acetic acid
• 英文别名: 2-(N-tert-butoxycarbonyl)-amino-2-(pyridin-3-yl)-acetic acid；2-N-tert-butoxycarbonyl-amino-2-pyridin-3-yl-acetic acid；N-tert-butoxycarbonyl-amino-2-(pyridin-3-yl)-acetic acid；(R,S)-tert-butoxycarbonylamino-pyridin-3-yl-acetic acid；N-Boc-amino-2-(pyridin-3-yl)-acetic acid；2-(Boc-amino)-2-(3-pyridinyl)acetic acid；2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-pyridin-3-ylacetic acid
• CAS: 347187-29-5
• 化学式: C₁₂H₁₆N₂O₄
• 分子量: 252.27
• InChiKey: ZHXKLUQXXPIZQU-UHFFFAOYSA-N

物化性质

• 沸点：
  440.9±40.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(Boc-氨基)-2-(3-吡啶)乙酸 在 N-甲基吗啉 、 吡啶 、 硼烷四氢呋喃络合物 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 36.0h， 生成 3-[1-(4-aminobutan-2-yl)piperidin-4-yl]-1-cyclohexyl-4-(pyridin-3-yl)imidazolidin-2-one
  参考文献：
  名称：

  Design of Substituted Imidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication

  摘要：

  The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (RS) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

  DOI：

  10.1021/jm401101p
• 作为产物：
  描述：

  3-吡啶乙酸乙酯 在 甲酸 、 亚硝酸特丁酯 、 水 、 sodium ethanolate 、 potassium hydroxide 、 锌 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 54.0h， 生成 2-(Boc-氨基)-2-(3-吡啶)乙酸
  参考文献：
  名称：

  Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides

  摘要：

  N-Benzyl 2-acetamido-2-substituted acetamides, where the 2-substituent is a (hetero) aromatic moiety, are potent anticonvulsants. We report the synthesis and whole animal pharmacological evaluation of 16 analogues where the terminal 2-acetyl group was removed to give the corresponding primary amino acid derivatives (PAADs). Conversion to the PAAD structure led to a substantial drop in seizure protection in animal tests, demonstrating the importance of the N-acetyl moiety for anticonvulsant activity. However, several of the PAADs displayed notable pain-attenuating activities in a mouse model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.002

文献信息

• [EN] NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE<br/>[FR] NOUVELLES SPIRO-IMIDAZOLONES EN TANT QU'ANTAGONISTES DE RÉCEPTEUR DE GLUCAGON, COMPOSITIONS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011119559A1

  公开（公告）日：2011-09-29

  The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

  本发明涉及一般式化合物，其中环A、环B、R1、R3、Z、L1和L2彼此独立选择，并如本文所定义，涉及包含该化合物的组合物，以及使用该化合物作为胰高血糖素受体拮抗剂以及用于治疗或预防2型糖尿病及相关疾病的方法。
• [DE] NEUE CARBONSÄUREAMIDE ALS FAKTOR XA-INHIBITOREN<br/>[EN] NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS<br/>[FR] NOUVEAUX CARBOXAMIDES COMME INHIBITEURS DU FACTEUR XA
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005082895A1

  公开（公告）日：2005-09-09

  Gegenstand der vorliegenden Erfindung sind neue substituierte Carbonsäureamide der allgemeinen Formel (I), in der A, B und R1 bis R5 wie in Anspruch 1 definiert sind, deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle Eigenschaften aufweisen. Die Verbindungen haben eine antithrombotische Wirkung uns sind Faktor Xa-Inhibitoren.

  The subject of the present invention is new substituted carboxylic acid amides of the general formula (I), in which A, B, and R1 to R5 are as defined in claim 1, their tautomers, their enantiomers, their diastereomers, their mixtures, and their salts, especially their physiologically acceptable salts with inorganic or organic acids or bases, which have valuable properties. The compounds have an antithrombotic effect and are Factor Xa inhibitors.
• New carboxylic acid amides, the preparation thereof and their use as medicaments
  申请人：Priepke Henning

  公开号：US20050203078A1

  公开（公告）日：2005-09-15

  The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R 1 to R 5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般式的新取代羧酸酰胺 其中A、B和R1至R5如权利要求1中定义，其互变异构体、对映体、非对映异构体、它们的混合物及其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的性质。
• Substituted hydantoins
  申请人：Chen Shaoqing

  公开号：US20070197617A1

  公开（公告）日：2007-08-23

  The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

  本发明涉及公式化合物的方法，其制备方法以及它们的使用方法。这些化合物在治疗由MEK高活性特征的疾病中很有用。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病中很有用。
• METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS
  申请人：Niu Huifeng

  公开号：US20080207563A1

  公开（公告）日：2008-08-28

  Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

  本文揭示了通过将肿瘤细胞与MEK抑制剂化合物和厄洛替尼接触，无论是顺序地还是同时地，协同抑制肿瘤细胞增殖的方法。还揭示了通过向人体逐步或同时施用厄洛替尼和MEK抑制剂化合物的方法，其中这些量在组合时对于协同抑制人体内肿瘤细胞增殖是有效的。